KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Implications of the API-CAT Trial for Extended Secondary Prophylaxis of Cancer-associated Venous Thromboembolism: Guidance from an Expert Panel. PMID 40774336 · Hamostaseologie · 2025-Aug-07 The record is an expert consensus/guidance paper on the API-CAT trial, not the original trial report. It discusses VTE recurrence as the efficacy endpoint, which is a safety/prophylaxis endpoint, not a standard oncology efficacy endpoint (OS, PFS, DFS). The report type is secondary (expert consensus).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague. PMID 40768716 · N Engl J Med · 2025-Aug-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial. PMID 40555465 · Gut · 2025-Aug-07 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase II trial of intravenous human dental pulp stem cell therapy for Huntington's disease: a randomized, double-blind, placebo-controlled study. PMID 40770775 · Stem Cell Res Ther · 2025-Aug-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Knee arthroplasty compared with joint distraction for osteoarthritis: a phase III randomized controlled trial. PMID 40763924 · Bone Jt Open · 2025-Aug-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial. PMID 40552814 · Antimicrob Agents Chemother · 2025-Aug-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. PMID 40530972 · Antimicrob Agents Chemother · 2025-Aug-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Design of a randomized tobacco cessation trial among FDNY World Trade Center responders in a lung cancer screening program. PMID 40765018 · Addict Sci Clin Pract · 2025-Aug-05 This is a trial protocol for a randomized smoking cessation study integrated into a lung cancer screening program. While it is randomized, involves humans, is oncology-related, and includes a drug (varenicline), it is not a report of results from a Phase III/IIIb or Phase II/III oncology randomized trial with a time-to-event efficacy endpoint. It lacks results and the primary outcomes are not time-to-event.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Heart Rhythm Monitoring Practices, Detection of Atrial Fibrillation, and Effect of Anticoagulation in the ARCADIA Trial. PMID 40728193 · J Am Heart Assoc · 2025-Aug-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA-MI Trial. PMID 40728174 · J Am Heart Assoc · 2025-Aug-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. PMID 40587141 · JAMA · 2025-Aug-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial. PMID 40814346 · Innovation (Camb) · 2025-Aug-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Trial: Genetic Resource for Precision Nutrition. PMID 40806132 · Nutrients · 2025-Aug-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study). PMID 40759981 · Trials · 2025-Aug-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis. PMID 40759562 · RMD Open · 2025-Aug-04 The study is a Phase III randomized trial of drugs (sarilumab vs. adalimumab) in humans, but it is not in oncology (it is in rheumatoid arthritis). It does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.); the primary focus is biomarker analysis. Therefore, it is excluded based on the non-oncology criterion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study. PMID 40759444 · J Immunother Cancer · 2025-Aug-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial. PMID 40759441 · J Immunother Cancer · 2025-Aug-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 3 trial. PMID 40624775 · J Sex Med · 2025-Aug-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A randomized, placebo-controlled phase III trial of an autologous, formalin-fixed tumor vaccine for newly diagnosed glioblastoma: trial protocol. PMID 40377260 · Jpn J Clin Oncol · 2025-Aug-03 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial. PMID 40752909 · Lancet · 2025-Aug-02 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L S B
旧组与严格 v3 交集 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
The Evolution of Randomized Clinical Trial Designs to Assess Therapeutics in Alzheimer Disease. PMID 40880087 · JAMA Netw Open · 2025-Aug-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Correction: Huang et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6-35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. Vaccines 2025, 13, 467. PMID 40872972 · Vaccines (Basel) · 2025-Aug-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The Impact of Nurse-Led Intervention on Breast Cancer Screening and Early Detection in China: Randomized Control Trial. PMID 40849715 · Asian Pac J Cancer Prev · 2025-Aug-01 The study is an oncology randomized trial in humans with original results, but it is excluded because: 1) The intervention is non-drug (nurse-led educational intervention, not a drug-containing therapy); 2) There is no explicit Phase III/IIIb or Phase II/III designation; 3) The primary endpoint is screening behavior/awareness (behavioral outcome), not a therapeutic time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Doctor's Counselling Using Culturally Responsive Pamphlet Increased Mammogram Uptake among Malay-Muslim Women in Singapore: A Randomized Controlled Trial in a Primary Healthcare Clinic. PMID 40849697 · Asian Pac J Cancer Prev · 2025-Aug-01 The record describes a randomized trial of doctor's counselling on mammogram uptake (a screening behaviour), not a drug intervention for treating a human malignant neoplasm. It is not a Phase III/IIIb or Phase II/III trial. The primary endpoint is mammogram uptake (a screening rate), not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Randomized Clinical Trial. PMID 40844778 · JAMA Netw Open · 2025-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials. PMID 40833694 · JAMA Netw Open · 2025-Aug-01 The record describes a secondary analysis of Phase III trial data. While it meets many criteria (oncology, human, randomized, Phase III, time-to-event endpoint), the intervention under study is statin use, not the original trial's drug intervention (apalutamide). This is not the primary report of the drug-containing trial's efficacy.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan. PMID 40833323 · Invest Ophthalmol Vis Sci · 2025-Aug-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy: The PRO-DUCE Randomized Clinical Trial. PMID 40815510 · JAMA Netw Open · 2025-Aug-01 The study is a randomized oncology trial with a drug intervention, but its primary and key secondary outcomes are quality-of-life and functional scales, not a formal time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Survival outcomes were mentioned only as unaffected secondary measures, not as the primary or key secondary efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Truncal Acne. PMID 40773616 · J Drugs Dermatol · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up. PMID 40750774 · Blood Cancer J · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Blunted exercise hyperemic response to lower limb exercise in individuals with Down syndrome. PMID 40588365 · Am J Physiol Heart Circ Physiol · 2025-Aug-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial. PMID 40569584 · JAMA Oncol · 2025-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial. PMID 40531517 · JAMA Oncol · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial. PMID 40531511 · JAMA Oncol · 2025-Aug-01 Study meets criteria for oncology, human, randomized, Phase 3, and original result, but is excluded because it is a non-drug-only intervention (stereotactic radiation therapy) and lacks a primary/key secondary time-to-event efficacy endpoint. The main outcomes are logistics and safety/toxicity.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. PMID 40531488 · JAMA Cardiol · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study. PMID 40473464 · J Nucl Med · 2025-Aug-01 The study is a Phase 3, prospective, multicenter diagnostic performance trial for a PET radiotracer. While it is oncology, human, and reports original results, it fails eligibility because it is not randomized, the intervention is not a drug (it's an imaging agent), and the primary endpoints are not time-to-event efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study. PMID 40473463 · J Nucl Med · 2025-Aug-01 The record describes a Phase II/III prospective imaging efficacy study for a diagnostic PET radiotracer. While it is an original oncology trial in humans, it fails two critical eligibility criteria: (1) it is not randomized, and (2) the intervention is not a drug therapy with a time-to-event efficacy endpoint. The primary endpoints are diagnostic sensitivity and specificity, not OS, PFS, or other time-to-event outcomes. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials. PMID 40471585 · JAMA Oncol · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium. PMID 40435111 · Clin Cancer Res · 2025-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Recovery from deep neuromuscular blockade using different sugammadex doses in elderly patients undergoing laparoscopic robot-assisted prostatectomy: A prospective, randomised, double-blind, phase III trial. PMID 40400264 · Eur J Anaesthesiol · 2025-Aug-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. PMID 40392969 · Clin Cancer Res · 2025-Aug-01 This record is a secondary biomarker analysis of the E1609 Phase III trial, not the original primary result report. While it references a Phase III trial with drug intervention and time-to-event endpoints, it does not present the original trial results. Randomization is implied but not explicitly confirmed in this abstract. Therefore, is_eligible is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial. PMID 40378056 · Clin Cancer Res · 2025-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab. PMID 40244828 · Rheumatology (Oxford) · 2025-Aug-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect size estimation in cooperative group- and industry-sponsored phase 3 oncology trials. PMID 40220316 · J Natl Cancer Inst · 2025-Aug-01 This is a meta-analysis/review article that aggregates data from multiple trials. It is not an original report of a single randomized trial with a drug intervention and a time-to-event efficacy endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Esophageal Toxicity After Dose-Escalated Radiation Therapy for Stage II-III Non-Small Cell Lung Cancer: A Secondary Analysis of the Phase 2 Randomized ARTFORCE PET-Boost Trial. PMID 40156600 · Int J Radiat Oncol Biol Phys · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study. PMID 40135473 · Int J Cancer · 2025-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Influence on Postoperative Results and Cost-effectiveness of Using Cyanoacrylate Glue for Pancreaticojejunal Anastomosis After Duodenopancreatectomy. PMID 40127250 · Pancreas · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Different Mediastinal Staging Modalities on Target Volume Delineation in Locally Advanced Non-Small Cell Lung Cancer: A Secondary Analysis of the Multicenter Randomized PET-Plan Trial. PMID 40054586 · Int J Radiat Oncol Biol Phys · 2025-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Bempedoic Acid for Hypercholesterolemia in Japan: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Trial. PMID 40024737 · J Atheroscler Thromb · 2025-Aug-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study. PMID 39924184 · J Atheroscler Thromb · 2025-Aug-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -